Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study

NCT01678027 Phase 3 ACTIVE_NOT_RECRUITING

This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence of gastric cancer in subjects with family history of gastric cancer.

Details

Lead sponsor	National Cancer Center, Korea
Phase	Phase 3
Status	ACTIVE_NOT_RECRUITING
Enrolment	1838
Start date	2004-11
Completion	2035-12

Conditions

• Gastric Cancer
• Helicobacter Pylori Infection
• Family Members

Interventions

• Placebo
• LAC triple therapy

Primary outcomes

• Gastric cancer incidence — 6 years after last participant enrollment
  The incidence of gastric cancer will be compared between the two arms as the participant assigned into either LAC treatment group or placebo group regardless the final H. pylori infection status. Currently, efficacy of LAC triple therapy shows about 75-85% eradication rate of the H. pylori.

Countries

South Korea